Published in Am J Clin Nutr on November 01, 2008
Macronutrient supplementation for malnourished HIV-infected adults: a review of the evidence in resource-adequate and resource-constrained settings. Clin Infect Dis (2009) 1.75
Impact of protein supplementation and care and support on body composition and CD4 count among HIV-infected women living in rural India: results from a randomized pilot clinical trial. AIDS Behav (2013) 0.92
Macronutrient supplementation and food prices in HIV treatment. J Nutr (2009) 0.92
Effects of nutritional supplementation for HIV patients starting antiretroviral treatment: randomised controlled trial in Ethiopia. BMJ (2014) 0.91
Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART? Am J Clin Nutr (2011) 0.87
Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression. Nutrients (2010) 0.85
Impact of nutritional supplementation on immune response, body mass index and bioelectrical impedance in HIV-positive patients starting antiretroviral therapy. Nutr J (2013) 0.80
Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab (2000) 11.97
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr (1996) 3.06
Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke (2006) 2.33
Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A (1997) 2.20
Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ (1999) 1.81
Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.79
Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis (2000) 1.74
Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition (1999) 1.66
Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis (2003) 1.62
Effect of indinavir on HIV-related wasting. AIDS (1998) 1.59
Clinical and immunologic effects of lipid-based parenteral nutrition in AIDS. JPEN J Parenter Enteral Nutr (1992) 1.46
Glucose requirements following burn injury. Parameters of optimal glucose infusion and possible hepatic and respiratory abnormalities following excessive glucose intake. Ann Surg (1979) 1.45
Parenteral nutrition for marrow transplant recipients: evaluation of an increased nitrogen dose. JPEN J Parenter Enteral Nutr (1991) 1.44
Long-term effects of early nutritional support with new enterotropic peptide-based formula vs. standard enteral formula in HIV-infected patients: randomized prospective trial. Nutrition (1994) 1.41
Progression of subclinical coronary atherosclerosis: does obesity make a difference? Circulation (2005) 1.27
Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis (2003) 1.27
Changes in nitrogen balance of depleted patients with increasing infusions of glucose. Am J Clin Nutr (1979) 1.24
The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS (1998) 1.17
Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis (2004) 1.16
Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr (2005) 1.14
Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr (2006) 1.12
Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J Clin Nutr (1995) 1.08
Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. Am J Epidemiol (2002) 1.07
Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens (2001) 0.99
Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr (1991) 0.96
Dietary intake and counseling, weight maintenance, and the course of HIV infection. J Am Diet Assoc (1995) 0.95
AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr (2003) 0.93
A randomized controlled trial evaluating nutrition counseling with or without oral supplementation in malnourished HIV-infected patients. J Am Diet Assoc (1998) 0.92
High-energy, high-protein, oral, liquid, nutrition supplementation in patients with HIV infection: effect on weight status in relation to incidence of secondary infection. J Am Diet Assoc (1996) 0.91
Impact of the nutritional regimen on protein catabolism and nitrogen balance in patients with acute renal failure. JPEN J Parenter Enteral Nutr (1996) 0.91
Effects of long-term supplementation with whey proteins on plasma glutathione levels of HIV-infected patients. Eur J Nutr (2002) 0.90
Effects of increasing nitrogen intake on nitrogen balance and energy expenditure in nutritionally depleted adult patients receiving parenteral nutrition. Am J Clin Nutr (1983) 0.89
Gastrostomy tube supplementation for HIV-infected children. Pediatrics (1995) 0.87
Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. J Trop Pediatr (2005) 0.87
A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab (1996) 0.86
Effects of whey protein and resistance exercise on body cell mass, muscle strength, and quality of life in women with HIV. AIDS (2001) 0.86
Protein intake is positively associated with body cell mass in weight-stable HIV-infected men. J Nutr (2003) 0.85
Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV-infected patients. Eur J Clin Invest (2000) 0.84
Effect of increased protein intake and nutritional status on whole-body protein metabolism of AIDS patients with weight loss. Metabolism (1995) 0.84
Whey proteins as a food supplement in HIV-seropositive individuals. Clin Invest Med (1993) 0.84
Effect of enteral tube feeding on growth of children with symptomatic human immunodeficiency virus infection. J Pediatr Gastroenterol Nutr (1994) 0.83
Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr (1990) 0.82
Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. Arch Intern Med (2005) 0.82
Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.82
Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: a randomized prospective trial. Eur J Clin Nutr (2001) 0.80
A multicenter case-controlled study of percutaneous endoscopic gastrostomy in HIV-seropositive patients. Am J Gastroenterol (1993) 0.79
Parenteral nutrition in septic patients: effect of increasing nitrogen intake. Am J Clin Nutr (1987) 0.78
Predictive markers of HIV-related weight loss and determination of differences between populations with weight loss stratified by opportunistic processes. J Acquir Immune Defic Syndr (1999) 0.77
Randomized, controlled trial of caloric supplements in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr (1999) 0.76
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis (2002) 5.34
Self-management interventions for chronic illness. Lancet (2004) 5.33
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med (2009) 4.54
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis (2007) 3.75
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 3.23
Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS (2005) 3.07
Effects of extended outpatient rehabilitation after hip fracture: a randomized controlled trial. JAMA (2004) 2.89
Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. J Am Geriatr Soc (2002) 2.80
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med (2003) 2.56
Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab (2004) 2.47
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS (2009) 2.29
Differential effects of resistance and endurance exercise in the fed state on signalling molecule phosphorylation and protein synthesis in human muscle. J Physiol (2008) 2.20
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis (2004) 2.17
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther (2002) 2.07
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis (2003) 2.04
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials (2008) 1.99
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood (2012) 1.89
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis (2007) 1.89
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS (2002) 1.79
Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr (2010) 1.67
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS (2003) 1.66
Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ (2006) 1.66
Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.65
The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS (2004) 1.64
The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis (2005) 1.64
Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis (2008) 1.63
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One (2010) 1.62
Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg (2009) 1.56
HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother (2010) 1.53
Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc (2010) 1.51
Insulin sensitivity by oral glucose minimal models: validation against clamp. Am J Physiol Endocrinol Metab (2005) 1.50
Mechanical ventilation depresses protein synthesis in the rat diaphragm. Am J Respir Crit Care Med (2004) 1.50
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab (2006) 1.49
Effects of progressive resistance training on body composition in frail older adults: results of a randomized, controlled trial. J Gerontol A Biol Sci Med Sci (2005) 1.48
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis (2007) 1.47
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Clin Infect Dis (2009) 1.46
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr (2014) 1.43
Current management challenges in HIV: antiretroviral resistance. AIDS Read (2003) 1.40
Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab (2009) 1.40
A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS (2002) 1.39
Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med (2013) 1.38
Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS (2010) 1.35
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS (2014) 1.34
The need to advance nutrition education in the training of health care professionals and recommended research to evaluate implementation and effectiveness. Am J Clin Nutr (2014) 1.34
Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res (2005) 1.33
Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom (2007) 1.33
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis (2011) 1.32
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One (2010) 1.30
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis (2006) 1.27
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr (2007) 1.27
Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis (2003) 1.27
Factors associated with weight loss after gastric bypass. Arch Surg (2008) 1.26
HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS (2007) 1.25
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab (2012) 1.24
Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation (2008) 1.24
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr (2014) 1.22
Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS (2002) 1.21
Exercise treatment to counteract protein wasting of chronic diseases. Curr Opin Clin Nutr Metab Care (2003) 1.21
Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab (2002) 1.20
Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS (2011) 1.18
The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res (2006) 1.18
Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2008) 1.17
Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.16
Age-related changes in bone morphology are accelerated in group VIA phospholipase A2 (iPLA2beta)-null mice. Am J Pathol (2008) 1.16
A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr Clin Pract (2012) 1.15
Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis (2006) 1.15
Whole-body proteolysis rate is elevated in HIV-associated insulin resistance. Diabetes (2006) 1.14
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr (2010) 1.14
The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther (2007) 1.13
Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care (2011) 1.13
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr (2009) 1.11
Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci (2010) 1.09
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis (2012) 1.09
The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution. Qual Life Res (2008) 1.07
Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial. AIDS Res Hum Retroviruses (2008) 1.07
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS (2007) 1.07
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol (2005) 1.06
HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr (2004) 1.06
Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab (2012) 1.04
Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle (2011) 1.03
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother (2012) 1.03
Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS (2007) 1.03